Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bertilimumab in moderate to extensive bullous pemphigoid
NCT02226146Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bertilimumab in Bullous Pemphigoid (BP), sponsored by Alexion Pharmaceuticals. Started Feb 2016; status: completed.
02
Drugs
bertilimumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT02226146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226146.